Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a smartphone app bring rehab to rare lung disease patients?

NCT ID NCT07799675

Disease control Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether an 8-week home-based telerehabilitation program, delivered through a mobile app, can safely improve exercise capacity in adults with pulmonary arterial hypertension (PAH). PAH causes severe shortness of breath and fatigue, and many patients cannot easily access supervised rehabilitation. The program includes three weekly sessions of breathing exercises, strength training, and aerobic walking, with one session live-supervised by video. Researchers will measure changes in peak oxygen consumption, walking distance, quality of life, and blood markers of inflammation to see if the approach helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
An 8-week home-based telerehabilitation program delivered via a mobile app, including respiratory physiotherapy, inspiratory muscle training, strength exercises, coordination, aerobic walking, and stretching.
What this could lead to
If it works, this could offer a safe, accessible way for people with pulmonary arterial hypertension to improve their exercise capacity and quality of life without needing to visit a clinic.
What could go wrong
This is a small, early-stage study with only 34 participants and no comparison group, so results may not apply broadly. Exercise carries some risk for people with heart and lung conditions, though the program is designed to be supervised and monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of stable pulmonary arterial hypertension (PAH). * Age 18 years or older. * Ability to use a smartphone or mobile application for the telerehabilitation program. * Signed informed consent. Exclusion Criteria: * Acute cardiorespiratory instability or medical contraindication to physical exercise. * Cognitive impairment or psychiatric disorders preventing comprehension or use of the telerehabilitation program. * Simultaneous participation in another interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary arterial hypertension (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary arterial hypertension (PAH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • FIMABIS

    Málaga, Málaga, 29007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.